Cagrilintide

Cagrilintide is an investigational, long-acting amylin analog designed to treat obesity and type 2 diabetes by curbing appetite and slowing digestion. Often combined with semaglutide (as CagriSema), it shows high efficacy, with studies indicating significant weight loss (up to ~22.7%) by improving satiety and reducing calorie intake.